SRFBP1

Summary

SRFBP1 (serum response factor binding protein 1, HGNC:26333) is a protein-coding gene on chromosome 5q23.1, encoding Serum response factor-binding protein 1 (Q8NEF9). May be involved in regulating transcriptional activation of cardiac genes during the aging process. It is a selective cancer dependency (DepMap: 86.5% of cell lines).

Enables RNA binding activity. Predicted to be involved in maturation of SSU-rRNA. Predicted to be located in perinuclear region of cytoplasm. Predicted to be part of 90S preribosome. Predicted to be active in nucleus.

Source: NCBI Gene 153443 — RefSeq curated summary.

At a glance

• GWAS associations: 9
• Clinical variants (ClinVar): 132 total — 2 pathogenic
• Cancer dependency (DepMap): dependent in 86.5% of screened cell lines
• MANE Select transcript: NM_152546

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:26333
Approved symbol	SRFBP1
Name	serum response factor binding protein 1
Location	5q23.1
Locus type	gene with protein product
Status	Approved
Aliases	FLJ25286, p49, STRAP, BUD22, Rlb1
Ensembl gene	ENSG00000151304
Ensembl biotype	protein_coding
OMIM	610479
Entrez	153443

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 4 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000339397, ENST00000504881, ENST00000919756, ENST00000919757, ENST00000959109

RefSeq mRNA: 1 — MANE Select: NM_152546 NM_152546

CCDS: CCDS43354

Canonical transcript exons

ENST00000339397 — 8 exons

Exon	Start	End
ENSE00000998845	122019260	122019341
ENSE00000998847	121994599	121994670
ENSE00000998849	122020088	122020802
ENSE00001082203	121975315	121975387
ENSE00001262053	121961975	121962068
ENSE00001370027	121974196	121974284
ENSE00001380332	122026942	122028633
ENSE00003587835	122022370	122022407

Expression profiles

Bgee: expression breadth ubiquitous, 235 present calls, max score 90.69.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 23.0124 / max 531.7029, expressed in 1784 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
58189	22.9837	1783
58190	0.0287	12

Top tissues by expression

252 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
calcaneal tendon	UBERON:0003701	90.69	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	86.57	gold quality
colonic epithelium	UBERON:0000397	83.61	gold quality
sural nerve	UBERON:0015488	83.16	gold quality
cauda epididymis	UBERON:0004360	82.41	gold quality
islet of Langerhans	UBERON:0000006	82.18	gold quality
corpus epididymis	UBERON:0004359	81.60	gold quality
caput epididymis	UBERON:0004358	81.52	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	80.95	gold quality
ventricular zone	UBERON:0003053	80.41	gold quality
adrenal tissue	UBERON:0018303	79.79	gold quality
monocyte	CL:0000576	79.65	gold quality
cartilage tissue	UBERON:0002418	79.62	gold quality
epithelial cell of pancreas	CL:0000083	79.27	gold quality
leukocyte	CL:0000738	79.24	gold quality
gastrocnemius	UBERON:0001388	78.98	gold quality
smooth muscle tissue	UBERON:0001135	78.92	gold quality
muscle of leg	UBERON:0001383	78.84	gold quality
ganglionic eminence	UBERON:0004023	77.60	gold quality
rectum	UBERON:0001052	77.56	gold quality
hindlimb stylopod muscle	UBERON:0004252	77.29	gold quality
stromal cell of endometrium	CL:0002255	77.14	gold quality
biceps brachii	UBERON:0001507	77.14	gold quality
vermiform appendix	UBERON:0001154	77.06	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	77.02	gold quality
mucosa of sigmoid colon	UBERON:0004993	76.94	gold quality
cortical plate	UBERON:0005343	76.60	gold quality
popliteal artery	UBERON:0002250	76.43	gold quality
tibial artery	UBERON:0007610	76.42	gold quality
lower lobe of lung	UBERON:0008949	76.16	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.67
E-MTAB-6379	no	523.68

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

77 targeting SRFBP1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872
HSA-MIR-548AM-3P	99.93	72.54	4872
HSA-MIR-548AQ-3P	99.93	72.66	4867
HSA-MIR-3671	99.90	73.04	3897
HSA-MIR-4496	99.88	68.89	2236
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-6124	99.87	69.78	3551
HSA-MIR-137-3P	99.87	74.74	2401
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-1273H-5P	99.77	66.32	2471
HSA-MIR-4679	99.76	69.19	1229
HSA-MIR-6752-3P	99.72	66.71	1587
HSA-MIR-149-3P	99.72	68.22	3963
HSA-MIR-494-3P	99.70	71.45	2795
HSA-MIR-4677-5P	99.70	70.09	1940
HSA-MIR-30B-3P	99.70	65.76	2325

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 86.5% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 5)

• p49/STRAP may be an important SRF cofactor in the transcriptional regulation of mammalian cardiac muscle genes throughout the life span (PMID:15492011)
• p49/STRAP plays a role in the regulation of intracellular processes such as cardiac cellular metabolism, gene expression, and possibly aging. (PMID:18230186)
• p49/STRAP can be considered a bona fide co-chaperone of Hsp70. (PMID:19751705)
• SRFBP1 is an HCV-specific, pan-genotypic host entry factor. (PMID:26212323)
• P49/STRAP expression was increased in the old versus young adult mouse hearts and also increased with advancing population doubling levels in cultured human umbilical vein endothelial cells. The increased expression of p49/STRAP in late life may alter the status of histone acetylation and impact mitochondrial dynamics and thereby reduce mitochondrial function and cardiac performance during mammalian senescence. (PMID:27337995)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	srfbp1	ENSDARG00000075323
mus_musculus	Srfbp1	ENSMUSG00000024528
rattus_norvegicus	Srfbp1	ENSRNOG00000014808
caenorhabditis_elegans	F18C12.3	WBGENE00008934

Protein

Protein identifiers

Serum response factor-binding protein 1 — Q8NEF9 (reviewed: Q8NEF9)

Alternative names: SRF-dependent transcription regulation-associated protein, p49/STRAP

All UniProt accessions (1): Q8NEF9

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in regulating transcriptional activation of cardiac genes during the aging process. May play a role in biosynthesis and/or processing of SLC2A4 in adipose cells.

Subunit / interactions. Interacts with SRF. Forms complexes with SRF and SRF cofactors ARID2, MYOCD and NKX2-5. Interacts with the N-terminus of SLC2A4.

Subcellular location. Cytoplasm. Perinuclear region.

Tissue specificity. Abundantly expressed in heart and skeletal muscle, and at much lower levels in brain and lung.

RefSeq proteins (1): NP_689759* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR015158	Bud22_dom	Domain
IPR037393	Bud22/SRFB1	Family

Pfam: PF09073

UniProt features (24 total): modified residue 9, compositionally biased region 6, region of interest 2, cross-link 2, coiled-coil region 2, initiator methionine 1, chain 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8NEF9-F1	62.20	0.23

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (11): 2, 203, 205, 264, 279, 281, 349, 351, 367, 190, 316

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 343 (showing top): GOBP_DIGESTION, GOBP_RIBOSOME_BIOGENESIS, GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_GROWTH_FACTOR_STIMULUS, REACTOME_SIGNALING_BY_TGF_BETA_RECEPTOR_COMPLEX, PAL_PRMT5_TARGETS_UP, MODULE_151, GOBP_MATURATION_OF_SSU_RRNA, GOBP_ALTERNATIVE_MRNA_SPLICING_VIA_SPLICEOSOME, MORF_UBE2I, GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_UP, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, DARWICHE_SKIN_TUMOR_PROMOTER_DN, DARWICHE_PAPILLOMA_RISK_LOW_DN, DARWICHE_PAPILLOMA_RISK_HIGH_DN, DARWICHE_SQUAMOUS_CELL_CARCINOMA_DN

GO Biological Process (1): maturation of SSU-rRNA (GO:0030490)

GO Molecular Function (1): RNA binding (GO:0003723)

GO Cellular Component (4): nucleus (GO:0005634), 90S preribosome (GO:0030686), perinuclear region of cytoplasm (GO:0048471), cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
rRNA processing	1
ribosomal small subunit biogenesis	1
nucleic acid binding	1
intracellular membrane-bounded organelle	1
preribosome	1
t-UTP complex	1
cytoplasm	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

2454 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SRFBP1	SRF	P11831	889
SRFBP1	CD81	P18582	764
SRFBP1	NKX2-5	P52952	675
SRFBP1	MYOCD	Q8IZQ8	669
SRFBP1	CCDC201	A0A1B0GTI1	604
SRFBP1	MYL2	P10916	582
SRFBP1	CAPN5	O15484	547
SRFBP1	NPC1L1	Q9UHC9	542
SRFBP1	ACTC1	P04270	542
SRFBP1	NPPA	P01160	538
SRFBP1	RBM44	Q6ZP01	520
SRFBP1	ASB17	Q8WXJ9	508
SRFBP1	CANX	P27824	505
SRFBP1	SLC2A4	P14672	481
SRFBP1	NRBP2	Q9NSY0	471

IntAct

66 interactions, top by confidence:

A	B	Type	Score
BYSL	PARN	psi-mi:“MI:0914”(association)	0.640
SRFBP1	DDX10	psi-mi:“MI:0914”(association)	0.640
N	NOP56	psi-mi:“MI:0914”(association)	0.530
N	RBM47	psi-mi:“MI:0914”(association)	0.530
RPS3	ZNF316	psi-mi:“MI:0914”(association)	0.530
FBL	ZNF316	psi-mi:“MI:0914”(association)	0.530
MAGEB2	POLRMT	psi-mi:“MI:0914”(association)	0.530
ABT1	ZNF316	psi-mi:“MI:0914”(association)	0.530
CD81	SRFBP1	psi-mi:“MI:0403”(colocalization)	0.430
H3C1	SMCHD1	psi-mi:“MI:2364”(proximity)	0.410
SMPD4	SRFBP1	psi-mi:“MI:0915”(physical association)	0.400
	SRFBP1	psi-mi:“MI:0915”(physical association)	0.370
SRFBP1		psi-mi:“MI:0915”(physical association)	0.370
CD81	HIP1R	psi-mi:“MI:0914”(association)	0.350
LCOR		psi-mi:“MI:0914”(association)	0.350
APP	ESYT2	psi-mi:“MI:0914”(association)	0.350
ESR1	ESYT2	psi-mi:“MI:0914”(association)	0.350
FBL	GXYLT2	psi-mi:“MI:0914”(association)	0.350
ITSN2	SNRPB2	psi-mi:“MI:0914”(association)	0.350
ARHGEF19	NUP42	psi-mi:“MI:0914”(association)	0.350
ARHGAP23	IPO8	psi-mi:“MI:0914”(association)	0.350
N	RBM47	psi-mi:“MI:0914”(association)	0.350

BioGRID (87): SRFBP1 (Affinity Capture-MS), SRFBP1 (Affinity Capture-MS), DDX10 (Affinity Capture-MS), FBXW5 (Affinity Capture-MS), SRFBP1 (Affinity Capture-MS), SRFBP1 (Proximity Label-MS), SRFBP1 (Affinity Capture-MS), SRFBP1 (Affinity Capture-MS), FBXW5 (Affinity Capture-MS), DDX10 (Affinity Capture-MS), SRFBP1 (Affinity Capture-RNA), SRFBP1 (Negative Genetic), SRFBP1 (Negative Genetic), SRFBP1 (Negative Genetic), SRFBP1 (Negative Genetic)

ESM2 similar proteins: A5PJN1, O57594, O75683, P0DPK0, P53352, P70279, Q05B65, Q0VCY3, Q17QR4, Q2KIV0, Q2TBX7, Q3KRF3, Q3U155, Q3ZCI6, Q58CQ0, Q5D1Z3, Q5NVE2, Q5R939, Q5RGP9, Q5XIB5, Q5XIG5, Q5ZIH9, Q5ZMG5, Q640V3, Q641W3, Q66H19, Q6NS45, Q6PK04, Q7ZWE7, Q8BG17, Q8BK35, Q8C6C7, Q8CIL4, Q8NDD1, Q8NEF9, Q8R0K4, Q8R2N0, Q8TF30, Q96J88, Q9CR02

Diamond homologs: Q05B65, Q5NVE2, Q5XGC9, Q66H19, Q8NEF9, Q9CZ91

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 73 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Major pathway of rRNA processing in the nucleolus and cytosol	11	14.2×	7e-08
Metabolism of RNA	8	7.0×	3e-03

GO biological processes:

GO term	Partners	Fold	FDR
ribosomal small subunit biogenesis	5	17.2×	9e-04
rRNA processing	6	12.9×	9e-04
RNA splicing	7	9.4×	9e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

132 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	0
Uncertain significance	90
Likely benign	14
Benign	1

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
1454248	NM_002317.7(LOX):c.1056T>G (p.Tyr352Ter)	Pathogenic
2706915	NM_002317.7(LOX):c.198dup (p.Gln67fs)	Pathogenic

SpliceAI

1751 predictions. Top by Δscore:

Variant	Effect	Δscore
5:121962066:GAG:G	donor_gain	1.0000
5:121962067:AGGTG:A	donor_loss	1.0000
5:121962069:GTGAG:G	donor_loss	1.0000
5:121962070:T:A	donor_loss	1.0000
5:121974191:CAAAG:C	acceptor_loss	1.0000
5:121974194:A:AG	acceptor_gain	1.0000
5:121974195:G:GA	acceptor_loss	1.0000
5:121974195:G:GG	acceptor_gain	1.0000
5:121974285:G:GG	donor_gain	1.0000
5:121974286:T:G	donor_gain	1.0000
5:121974299:G:GG	donor_gain	1.0000
5:121975309:TTGCA:T	acceptor_loss	1.0000
5:121975310:TGCA:T	acceptor_loss	1.0000
5:121975311:GCA:G	acceptor_loss	1.0000
5:121975312:CA:C	acceptor_loss	1.0000
5:121975313:A:AG	acceptor_gain	1.0000
5:121975313:A:C	acceptor_loss	1.0000
5:121975313:AG:A	acceptor_gain	1.0000
5:121975313:AGG:A	acceptor_gain	1.0000
5:121975313:AGGG:A	acceptor_gain	1.0000
5:121975314:G:GA	acceptor_gain	1.0000
5:121975314:GG:G	acceptor_gain	1.0000
5:121975314:GGG:G	acceptor_gain	1.0000
5:121975314:GGGG:G	acceptor_gain	1.0000
5:121975314:GGGGT:G	acceptor_gain	1.0000
5:121975384:GAAG:G	donor_gain	1.0000
5:121975385:AAGG:A	donor_loss	1.0000
5:121975386:AGGT:A	donor_loss	1.0000
5:121975388:G:GG	donor_gain	1.0000
5:121975388:G:T	donor_loss	1.0000

AlphaMissense

2835 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
5:122027115:T:C	F427L	0.997
5:122027117:T:A	F427L	0.997
5:122027117:T:G	F427L	0.997
5:122027048:G:C	W404C	0.996
5:122027048:G:T	W404C	0.996
5:122027046:T:A	W404R	0.992
5:122027046:T:C	W404R	0.992
5:122027039:T:A	H401Q	0.991
5:122027039:T:G	H401Q	0.991
5:122027094:T:C	F420L	0.991
5:122027096:T:A	F420L	0.991
5:122027096:T:G	F420L	0.991
5:121974210:A:C	R17S	0.990
5:121974210:A:T	R17S	0.990
5:122027116:T:G	F427C	0.989
5:121974230:G:C	R24P	0.987
5:121974245:G:C	R29P	0.987
5:122027037:C:G	H401D	0.986
5:121974209:G:C	R17T	0.985
5:122027116:T:C	F427S	0.985
5:121974251:T:C	L31P	0.984
5:122020525:A:C	S264R	0.983
5:122020527:C:A	S264R	0.983
5:122020527:C:G	S264R	0.983
5:122027038:A:G	H401R	0.983
5:121975350:G:C	R54P	0.982
5:122019284:G:C	A99P	0.982
5:121975379:G:C	A64P	0.981
5:121975387:G:C	K66N	0.981
5:121975387:G:T	K66N	0.981

dbSNP variants (sampled 300 via entrez): RS1000006036 (5:122013043 T>C), RS1000011531 (5:122049480 T>C,G), RS1000019257 (5:122057961 T>C), RS1000032176 (5:122035556 C>G), RS1000032200 (5:122013256 C>A), RS1000070629 (5:121976684 A>G), RS1000104710 (5:122005457 A>G), RS1000121769 (5:122054847 C>T), RS1000130449 (5:122052278 T>C), RS1000137741 (5:121981515 C>A), RS1000154204 (5:122079164 A>T), RS1000226773 (5:121981772 AG>A), RS1000293916 (5:122021132 A>G), RS1000341950 (5:122023934 G>A,C), RS1000356773 (5:121987114 T>A)

Disease associations

OMIM: gene MIM:610479 | disease phenotypes: MIM:617168, MIM:607086

GenCC curated gene-disease

Mondo (3): aortic aneurysm, familial thoracic 10 (MONDO:0014950), familial thoracic aortic aneurysm and aortic dissection (MONDO:0019625), pulmonary emphysema (MONDO:0004849)

Orphanet (1): Familial thoracic aortic aneurysm and aortic dissection (Orphanet:91387)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

9 associations (top):

Study	Trait	p-value
GCST005196_86	Coronary artery disease	4.000000e-08
GCST007096_124	Pulse pressure	9.000000e-09
GCST007097_81	Pulse pressure	4.000000e-06
GCST007097_82	Pulse pressure	4.000000e-06
GCST007099_167	Systolic blood pressure	2.000000e-06
GCST011365_127	Myocardial infarction	1.000000e-06
GCST012226_58	Waist circumference adjusted for body mass index	3.000000e-09
GCST012226_59	Waist circumference adjusted for body mass index	2.000000e-08
GCST90013442_7	Keratoconus	2.000000e-20

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0005763	pulse pressure measurement
EFO:0006335	systolic blood pressure
EFO:0007789	BMI-adjusted waist circumference

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D004646	Emphysema	C23.550.325
D011656	Pulmonary Emphysema	C08.381.495.389.750; C23.550.291.500.875.875

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

31 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects binding, increases reaction, increases abundance, increases expression	2
Tetrachlorodibenzodioxin	affects expression, decreases expression	2
Cadmium Chloride	increases expression	2
aristolochic acid I	decreases expression	1
FR900359	affects phosphorylation	1
dicrotophos	decreases expression	1
triphenyl phosphate	affects expression	1
deoxynivalenol	increases expression	1
arsenite	affects binding, decreases reaction	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
di-n-butylphosphoric acid	affects expression	1
cylindrospermopsin	increases expression	1
abrine	decreases expression, increases expression	1
jinfukang	affects cotreatment, decreases expression	1
Sunitinib	increases expression	1
Leflunomide	increases expression	1
Air Pollutants	decreases expression, increases abundance	1
Arsenic	increases abundance, increases expression	1
Caffeine	decreases phosphorylation	1
Cisplatin	affects cotreatment, decreases expression	1
Estradiol	increases expression	1
Hydrogen Peroxide	affects expression	1
Phenobarbital	affects expression	1
Ribonucleotides	affects binding	1
T-2 Toxin	increases expression	1
Thiram	increases expression	1
Valproic Acid	increases expression	1
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	affects expression	1
Cyclosporine	increases expression	1
Aflatoxin M1	decreases expression	1

Clinical trials (associated diseases)

286 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00175565	PHASE4	COMPLETED	Inhaled Steroid Reduces Systemic Inflammation in COPD
NCT00181207	PHASE4	COMPLETED	Airway Clearance for Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation
NCT00261833	PHASE4	COMPLETED	Zemaira in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor Deficiency
NCT00424528	PHASE4	COMPLETED	Efficacy Safety Study of Arformoterol/Tiotropium Combination Versus Either Therapy Alone in Chronic Obstructive Pulmonary Disease (COPD)
NCT00633776	PHASE4	WITHDRAWN	Perforomist Versus Foradil Evaluated by Inspiratory Capacity and High Resolution Computed Tomography (HRCT)
NCT00670007	PHASE4	COMPLETED	Extension Study of Zemaira® i.v. Administration in Subjects With Emphysema Due to alpha1-proteinase Inhibitor Deficiency.
NCT00680056	PHASE4	COMPLETED	Add-on Effects of Tiotropium Over Formoterol in Exercise Tolerance on Chronic Obstructive Pulmonary Disease Patients
NCT00680641	PHASE4	UNKNOWN	Simvastatin in Chronic Obstructive Pulmonary Disease (COPD)
NCT00720226	PHASE4	COMPLETED	Efficacy of Losartan in Preventing Progression of COPD
NCT00730301	PHASE4	UNKNOWN	EUROPT Clinical Trial to Study the Efficacy of One-Way Valve Implantation (New Treatment Algorithm) in Patients With Heterogeneous Emphysema
NCT00857038	PHASE4	UNKNOWN	Doxycycline and Airway Inflammation in Chronic Obstructive Pulmonary Disease (COPD)
NCT01336283	PHASE4	COMPLETED	Effectiveness of Different Exercise Training Programs to the Profile of COPD Patients
NCT01361984	PHASE4	UNKNOWN	Sunovion Brovana Versus Serevent Inspiratory Capacity High Resolution Computed Tomography
NCT01431625	PHASE4	UNKNOWN	Effects of Exercise Training on Systemic Inflammation an Muscle Repair According to the Obstructive Chronic Pulmonary Disease (COPD) Phenotype
NCT01460108	PHASE4	UNKNOWN	AeriSeal System in Patients With Advanced Upper Lobe Predominant Emphysema and Collateral Ventilation
NCT01466712	PHASE4	UNKNOWN	Evaluate the Effects of Formoterol and Beclomethasone Dipropionate Combination Therapy on Small Airways Function
NCT01520740	PHASE4	TERMINATED	Collateral Ventilation Effects on Response to AeriSeal System Treatment in Upper Lobe Predominant Emphysema
NCT02682147	PHASE4	ACTIVE_NOT_RECRUITING	Functional CT Assessment of Pulmonary Arterial Dysfunction in Smoking Associated Emphysema
NCT02696564	PHASE4	COMPLETED	Losartan Effects on Emphysema Progression
NCT03073798	PHASE4	COMPLETED	The Effectiveness of Roflumilast in Improving Mucociliary Clearance in Patients With COPD and Chronic Bronchitis
NCT03382106	PHASE4	COMPLETED	Smoking Cessation and Functional CT Assessment
NCT03733470	PHASE4	COMPLETED	Hypoxic Pulmonary Vasoconstriction Pilot Study
NCT07326592	PHASE4	NOT_YET_RECRUITING	Phase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung Density Decline Rates of Respreeza / Zemaira Weekly for 3 Years in Adults With alpha1 Antitrypsin Deficiency (AATD)
NCT00000606	PHASE3	COMPLETED	National Emphysema Treatment Trial (NETT)
NCT00064402	PHASE3	COMPLETED	Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD
NCT00064415	PHASE3	COMPLETED	To Evaluate the Long-term Safety of (R,R)-Formoterol in Subjects With COPD
NCT00129584	PHASE3	COMPLETED	Endobronchial Valve for Emphysema Palliation Trial (VENT)
NCT00137956	PHASE3	TERMINATED	Endobronchial Valve for Emphysema PalliatioN Trial (VENT) Cost-effectiveness Sub-Study
NCT00188825	PHASE3	COMPLETED	Study Comparing Simulect Plus Standard Immunosuppression to Standard Immunosuppression Alone for the Prevention of Acute Rejection and Bronchiolitis Obliterans in Lung Transplant
NCT00250679	PHASE3	COMPLETED	Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease
NCT00288964	PHASE3	WITHDRAWN	Use of the Hattler Respiratory Assist Catheter in Severe Respiratory Failure
NCT00391612	PHASE3	UNKNOWN	EASE Trial: Exhale Airway Stents for Emphysema
NCT00613860	PHASE3	WITHDRAWN	Sequential Endoscopic Lung Volume Reduction
NCT01449292	PHASE3	TERMINATED	Study of the AeriSeal System for HyPerInflation Reduction in Emphysema (ASPIRE)
NCT01602523	PHASE3	UNKNOWN	Effect of Symbicort on Sleep Quality in Patients With Emphysema
NCT01822795	PHASE3	UNKNOWN	Lung Volume Reduction Coil Treatment in Emphysema.
NCT01869205	PHASE3	COMPLETED	The Effect and Mechanism of Bronchoscopic Lung Volume Reduction by Endobronchial Valve in Korean Emphysema Patients
NCT01908933	PHASE3	WITHDRAWN	Study of the AeriSeal System Treatment in Patients With Advanced Non-Upper Lobe Predominant Heterogeneous Emphysema
NCT02261350	PHASE3	TERMINATED	Post-hospitalisation Nutritional Support and Gait Speed in COPD
NCT00000573	PHASE2	COMPLETED	Emphysema: Physiologic Effects of Nutritional Support